Highlights of This Issue 2675

SMALL MOLECULE THERAPEUTICS

2677 Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
Rebecca A. Previs, Guillermo N. Armaiz-Pena, Yvonne G. Lin, Ashley N. Davis, Sunila Pradeep, Heather J. Dalton, Robert L. Coleman, and Anil K. Sood

2687 Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Kazuharu Kai, Kimie Kondo, Xiaoping Wang, Xuemei Xie, Mary K. Pitner, Monica E. Reyes, Angie M. Torres-Adorno, Hiroko Masuda, Gabriel N. Hortobagyi, Chandra Bartholomeusz, Hideyuki Saya, Deb Shipton, Subrata Sen, and Naoto T. Ueno

2700 Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Steven R. Whittaker, Glenn S. Cowley, Steve Wagner, Flora Luo, David E. Root, and Levi A. Garraway

2712 Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Matthias Ilmer, Agnes Garnier, Jody Vykoukal, Eckhard Alt, Dietrich von Schweinitz, Roland Kappler, and Michael Berger

2722 Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling
Dhanya K. Nambiar, Paulraj Rajamani, Gagan Deep, Anil K. Jain, Rajesh Agarwal, and Rana P. Singh

2735 Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

2744 The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo
Heather Venant, Mehrdad Rahmaniyan, E. Ellen Jones, Ping Lu, Michael B. Lilly, Elizabeth Garrett-Mayer, Richard R. Drake, Jacqueline M. Kavalek, Charles D. Smith, and Christina Voelkel-Johnson

2753 Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer
Brian Gabrielli, Fawzi Bokhari, Max V. Ranall, Zay Yar Oo, Alexander J. Stevenson, WeiLi Wang, Melanie Murrell, Mushfiq Shaikh, Sora Fallaha, Daniel Clarke, Madison Kelly, Karin Seidelis, Melinda Christensen, Sara McKe, Graham Leggatt, Paul Leo, Dubravka Skalamera, H. Peter Soyer, Thomas J. Gonda, and Nigel A.J. McMillan

2762 BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis
Michael P. Sanderson, Joshua Appar, Pilar Garin-Chesa, Marco H. Hofmann, Dirk Kessler, Jens Quanti, Alexander Savchenko, Otmar Schaaf, Matthias Treu, Heather Tye, Stephan K. Zahn, Andreas Zoepf, Eric Haakisma, Günther R. Adolf, and Norbert Kraut

LARGE MOLECULE THERAPEUTICS

2782 High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study
Sylvain Manfredi, Olivier Bouché, Philippe Rougier, Laetitia Daham, Marie Anne Loriot, Thomas Aparicio, Pierre Luc Etienne, Jean Pierre Lafargue, Cedric Lécaillé, Jean Louis Legoux, Karine Le Malicot, Emilie Maillard, Thierry Lecomte, Faiza Khemissa, Gilles Breysacher, Pierre Michel, Emmanuel Misty, and Laurent Bedenne

2789 Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors
Ronit Mazor, Jingli Zhang, Laimaian Xiang, Selamawit Addissie, Prince Awoah, Richard Breen, Raffi Hassan, and Ira Pastan
Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer–siRNA Chimeras in Human Tumor Xenografts
Xiaohua Ni, Yonggang Zhang, Kenji Zennami, Mark Castanares, Amarnath Mukherjee, Raju R. Raval, Haoming Zhou, Theodore L. DeWeese, and Shawn E. Lupold

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma
Wei Jiang, Na Li, Xiao-Zhong Chen, Ying Sun, Bin Li, Xian-Yue Ren, Wei-Feng Qin, Ning Jiang, Ya-Fei Xu, Ying-Qin Li, Jian Ren, William CS Cho, Jing-Ping Yan, Jing Zeng, Li-Zhi Liu, Li Li, Ying Guo, Hai-Qiang Mai, Mu-Sheng Zeng, Tie-Rang Kang, Wei-Hua Jia, Jian-Yong Shao, and Jun Ma

Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients
Tongmeng Yan, Linlin Lu, Cong Xie, Jianwei Chen, Xiaoqian Peng, Lijun Zhu, Ying Wang, Qiang Li, Jian Shi, Fuyuan Zhou, Ming Hu, and Zhongqiu Liu

Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing

Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model

Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
Vlad C. Sandulache, Yunyun Chen, Heath D. Skinner, Tongtong Lu, Lei Feng, Laurence E. Court, Jeffrey N. Myers, Raymond E. Meyn, Clifton D. Fuller, James A. Bankson, and Stephen Y. Lai

Acknowledgment to Reviewers

For more information please visit www.aacrbjournals.org
ABOUT THE COVER

The cover image shows the structural model of LMB-T20, a highly potent recombinant immunotoxin consisting of an antimesothelin Fv fused to a portion of Pseudomonas exotoxin A. The toxin has a deletion of domain II and six point mutations in domain III that delete or greatly suppress the eight T-cell epitopes. For details, see the article by Mazor and colleagues on page 2789.
Molecular Cancer Therapeutics

14 (12)

Mol Cancer Ther 2015;14:2675-2912.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/14/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/14/12. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.